{"generated":"2026-09-28T07:14:13.437Z","checked":{"drugs":1024,"trials":5791},"mismatches":[{"check":"trial-status-vs-registry","id":"bonner-cetuximab-rt","name":"Bonner trial (cetuximab plus radiotherapy)","route":"/trials/bonner-cetuximab-rt/","recorded":"positive","registry":"TERMINATED","url":"https://clinicaltrials.gov/study/NCT00004227","severity":"high"},{"check":"trial-status-vs-registry","id":"clocc","name":"CLOCC","route":"/trials/clocc/","recorded":"positive","registry":"TERMINATED","url":"https://clinicaltrials.gov/study/NCT00043004","severity":"high"},{"check":"trial-status-vs-registry","id":"cyto-pv","name":"CYTO-PV","route":"/trials/cyto-pv/","recorded":"positive","registry":"TERMINATED","url":"https://clinicaltrials.gov/study/NCT01645124","severity":"high"},{"check":"trial-status-vs-registry","id":"destiny-lung01","name":"DESTINY-Lung01","route":"/trials/destiny-lung01/","recorded":"positive","registry":"TERMINATED","url":"https://clinicaltrials.gov/study/NCT03505710","severity":"high"},{"check":"trial-status-vs-registry","id":"keynote-057","name":"KEYNOTE-057","route":"/trials/keynote-057/","recorded":"positive","registry":"TERMINATED","url":"https://clinicaltrials.gov/study/NCT02625961","severity":"high"},{"check":"trial-status-vs-registry","id":"rockstar","name":"ROCKstar","route":"/trials/rockstar/","recorded":"positive","registry":"TERMINATED","url":"https://clinicaltrials.gov/study/NCT03640481","severity":"high"},{"check":"trial-status-vs-registry","id":"tower","name":"TOWER","route":"/trials/tower/","recorded":"positive","registry":"TERMINATED","url":"https://clinicaltrials.gov/study/NCT02013167","severity":"high"},{"check":"enrolled-vs-registry","id":"nct06109272","name":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","route":"/trials/nct06109272/","recorded":"enrolled 660","registry":"enrolment 89 (actual)","url":"https://clinicaltrials.gov/study/NCT06109272","severity":"medium"},{"check":"enrolled-vs-registry","id":"abc-02","name":"ABC-02","route":"/trials/abc-02/","recorded":"enrolled 410","registry":"enrolment 324 (actual)","url":"https://clinicaltrials.gov/study/NCT00262769","severity":"medium"},{"check":"enrolled-vs-registry","id":"acosog-z0011","name":"ACOSOG Z0011 (Alliance)","route":"/trials/acosog-z0011/","recorded":"enrolled 891","registry":"enrolment 605 (actual)","url":"https://clinicaltrials.gov/study/NCT00003855","severity":"medium"},{"check":"enrolled-vs-registry","id":"alphabreak","name":"AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)","route":"/trials/alphabreak/","recorded":"enrolled 600","registry":"enrolment 110 (actual)","url":"https://clinicaltrials.gov/study/NCT06402331","severity":"medium"},{"check":"enrolled-vs-registry","id":"amaros","name":"AMAROS (EORTC 10981-22023)","route":"/trials/amaros/","recorded":"enrolled 1425","registry":"enrolment 4813 (actual)","url":"https://clinicaltrials.gov/study/NCT00014612","severity":"medium"},{"check":"enrolled-vs-registry","id":"amplify","name":"AMPLIFY","route":"/trials/amplify/","recorded":"enrolled 867","registry":"enrolment 984 (actual)","url":"https://clinicaltrials.gov/study/NCT03836261","severity":"medium"},{"check":"enrolled-vs-registry","id":"armor3-sv","name":"ARMOR3-SV","route":"/trials/armor3-sv/","recorded":"enrolled 38","registry":"enrolment 953 (actual)","url":"https://clinicaltrials.gov/study/NCT02438007","severity":"medium"},{"check":"enrolled-vs-registry","id":"ascent-03","name":"ASCENT-03","route":"/trials/ascent-03/","recorded":"enrolled 558","registry":"enrolment 623 (actual)","url":"https://clinicaltrials.gov/study/NCT05382299","severity":"medium"},{"check":"enrolled-vs-registry","id":"astra","name":"ASTRA","route":"/trials/astra/","recorded":"enrolled 401","registry":"enrolment 233 (actual)","url":"https://clinicaltrials.gov/study/NCT01843062","severity":"medium"},{"check":"enrolled-vs-registry","id":"athena-mono","name":"ATHENA-MONO / GOG-3020","route":"/trials/athena-mono/","recorded":"enrolled 538","registry":"enrolment 1097 (actual)","url":"https://clinicaltrials.gov/study/NCT03522246","severity":"medium"},{"check":"enrolled-vs-registry","id":"blue-c","name":"BLUE-C","route":"/trials/blue-c/","recorded":"enrolled 20176","registry":"enrolment 26758 (actual)","url":"https://clinicaltrials.gov/study/NCT04144738","severity":"medium"},{"check":"enrolled-vs-registry","id":"bonner-cetuximab-rt","name":"Bonner trial (cetuximab plus radiotherapy)","route":"/trials/bonner-cetuximab-rt/","recorded":"enrolled 424","registry":"enrolment 32 (actual)","url":"https://clinicaltrials.gov/study/NCT00004227","severity":"medium"},{"check":"enrolled-vs-registry","id":"brf113928","name":"BRF113928 cohort C (dabrafenib with trametinib, untreated BRAF V600E)","route":"/trials/brf113928/","recorded":"enrolled 36","registry":"enrolment 177 (actual)","url":"https://clinicaltrials.gov/study/NCT01336634","severity":"medium"},{"check":"enrolled-vs-registry","id":"c-144-01","name":"C-144-01","route":"/trials/c-144-01/","recorded":"enrolled 153","registry":"enrolment 220 (actual)","url":"https://clinicaltrials.gov/study/NCT02360579","severity":"medium"},{"check":"enrolled-vs-registry","id":"ca184-043-ipilimumab","name":"CA184-043","route":"/trials/ca184-043-ipilimumab/","recorded":"enrolled 799","registry":"enrolment 988 (actual)","url":"https://clinicaltrials.gov/study/NCT00861614","severity":"medium"},{"check":"enrolled-vs-registry","id":"calgb-80405","name":"CALGB/SWOG 80405","route":"/trials/calgb-80405/","recorded":"enrolled 1137","registry":"enrolment 2334 (actual)","url":"https://clinicaltrials.gov/study/NCT00265850","severity":"medium"},{"check":"enrolled-vs-registry","id":"cambria","name":"CAMBRIA-1 & CAMBRIA-2","route":"/trials/cambria/","recorded":"enrolled 10000","registry":"enrolment 5511 (actual)","url":"https://clinicaltrials.gov/study/NCT05952557","severity":"medium"},{"check":"enrolled-vs-registry","id":"capitello-291","name":"CAPItello-291","route":"/trials/capitello-291/","recorded":"enrolled 708","registry":"enrolment 818 (actual)","url":"https://clinicaltrials.gov/study/NCT04305496","severity":"medium"},{"check":"enrolled-vs-registry","id":"cartitude-1","name":"CARTITUDE-1","route":"/trials/cartitude-1/","recorded":"enrolled 97","registry":"enrolment 126 (actual)","url":"https://clinicaltrials.gov/study/NCT03548207","severity":"medium"},{"check":"enrolled-vs-registry","id":"caspian","name":"CASPIAN","route":"/trials/caspian/","recorded":"enrolled 805","registry":"enrolment 987 (actual)","url":"https://clinicaltrials.gov/study/NCT03043872","severity":"medium"},{"check":"enrolled-vs-registry","id":"cemiplimab-advanced-bcc","name":"Cemiplimab in basal cell carcinoma after a hedgehog inhibitor","route":"/trials/cemiplimab-advanced-bcc/","recorded":"enrolled 84","registry":"enrolment 138 (actual)","url":"https://clinicaltrials.gov/study/NCT03132636","severity":"medium"},{"check":"enrolled-vs-registry","id":"checkmate-143","name":"CheckMate 143","route":"/trials/checkmate-143/","recorded":"enrolled 369","registry":"enrolment 529 (actual)","url":"https://clinicaltrials.gov/study/NCT02017717","severity":"medium"},{"check":"enrolled-vs-registry","id":"checkmate-205","name":"CheckMate 205","route":"/trials/checkmate-205/","recorded":"enrolled 243","registry":"enrolment 294 (actual)","url":"https://clinicaltrials.gov/study/NCT02181738","severity":"medium"},{"check":"enrolled-vs-registry","id":"checkmate-649","name":"CheckMate 649","route":"/trials/checkmate-649/","recorded":"enrolled 1581","registry":"enrolment 2031 (actual)","url":"https://clinicaltrials.gov/study/NCT02872116","severity":"medium"},{"check":"enrolled-vs-registry","id":"checkmate-816","name":"CheckMate 816","route":"/trials/checkmate-816/","recorded":"enrolled 358","registry":"enrolment 505 (actual)","url":"https://clinicaltrials.gov/study/NCT02998528","severity":"medium"},{"check":"enrolled-vs-registry","id":"chronos","name":"CHRONOS","route":"/trials/chronos/","recorded":"enrolled 27","registry":"enrolment 32 (actual)","url":"https://clinicaltrials.gov/study/NCT03227926","severity":"medium"},{"check":"enrolled-vs-registry","id":"clarinet","name":"CLARINET","route":"/trials/clarinet/","recorded":"enrolled 204","registry":"enrolment 264 (actual)","url":"https://clinicaltrials.gov/study/NCT00353496","severity":"medium"},{"check":"enrolled-vs-registry","id":"nct06422936","name":"Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)","route":"/trials/nct06422936/","recorded":"enrolled 60","registry":"enrolment 50 (actual)","url":"https://clinicaltrials.gov/study/NCT06422936","severity":"medium"},{"check":"enrolled-vs-registry","id":"codebreak-100","name":"CodeBreaK 100 (pancreatic cancer cohort)","route":"/trials/codebreak-100/","recorded":"enrolled 38","registry":"enrolment 713 (actual)","url":"https://clinicaltrials.gov/study/NCT03600883","severity":"medium"},{"check":"enrolled-vs-registry","id":"anbl0032","name":"COG ANBL0032","route":"/trials/anbl0032/","recorded":"enrolled 226","registry":"enrolment 1449 (actual)","url":"https://clinicaltrials.gov/study/NCT00026312","severity":"medium"},{"check":"enrolled-vs-registry","id":"columbus","name":"COLUMBUS","route":"/trials/columbus/","recorded":"enrolled 577","registry":"enrolment 921 (actual)","url":"https://clinicaltrials.gov/study/NCT01909453","severity":"medium"},{"check":"enrolled-vs-registry","id":"deep-c","name":"DeeP-C","route":"/trials/deep-c/","recorded":"enrolled 9989","registry":"enrolment 12776 (actual)","url":"https://clinicaltrials.gov/study/NCT01397747","severity":"medium"},{"check":"enrolled-vs-registry","id":"destiny-pantumor02","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/","recorded":"enrolled 267","registry":"enrolment 477 (actual)","url":"https://clinicaltrials.gov/study/NCT04482309","severity":"medium"},{"check":"enrolled-vs-registry","id":"duo-e","name":"DUO-E / GOG-3041 / ENGOT-EN10","route":"/trials/duo-e/","recorded":"enrolled 718","registry":"enrolment 805 (actual)","url":"https://clinicaltrials.gov/study/NCT04269200","severity":"medium"},{"check":"enrolled-vs-registry","id":"duo-o","name":"DUO-O / ENGOT-ov46","route":"/trials/duo-o/","recorded":"enrolled 1130","registry":"enrolment 1407 (actual)","url":"https://clinicaltrials.gov/study/NCT03737643","severity":"medium"},{"check":"enrolled-vs-registry","id":"nct06050122","name":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","route":"/trials/nct06050122/","recorded":"enrolled 140","registry":"enrolment 113 (actual)","url":"https://clinicaltrials.gov/study/NCT06050122","severity":"medium"},{"check":"enrolled-vs-registry","id":"emerald-1","name":"EMERALD-1","route":"/trials/emerald-1/","recorded":"enrolled 616","registry":"enrolment 724 (actual)","url":"https://clinicaltrials.gov/study/NCT03778957","severity":"medium"},{"check":"enrolled-vs-registry","id":"empower-cscc-1","name":"EMPOWER-CSCC-1","route":"/trials/empower-cscc-1/","recorded":"enrolled 193","registry":"enrolment 432 (actual)","url":"https://clinicaltrials.gov/study/NCT02760498","severity":"medium"},{"check":"enrolled-vs-registry","id":"enthuse-m1-zibotentan","name":"ENTHUSE M1","route":"/trials/enthuse-m1-zibotentan/","recorded":"enrolled 594","registry":"enrolment 896 (actual)","url":"https://clinicaltrials.gov/study/NCT00554229","severity":"medium"},{"check":"enrolled-vs-registry","id":"eortc-22033","name":"EORTC 22033-26033","route":"/trials/eortc-22033/","recorded":"enrolled 477","registry":"enrolment 709 (actual)","url":"https://clinicaltrials.gov/study/NCT00182819","severity":"medium"},{"check":"enrolled-vs-registry","id":"epcore-dlbcl-1","name":"EPCORE DLBCL-1","route":"/trials/epcore-dlbcl-1/","recorded":"enrolled 552","registry":"enrolment 483 (actual)","url":"https://clinicaltrials.gov/study/NCT04628494","severity":"medium"},{"check":"enrolled-vs-registry","id":"epcore-nhl-1","name":"EPCORE NHL-1","route":"/trials/epcore-nhl-1/","recorded":"enrolled 157","registry":"enrolment 666 (actual)","url":"https://clinicaltrials.gov/study/NCT03625037","severity":"medium"},{"check":"enrolled-vs-registry","id":"esphall","name":"EsPhALL (EsPhALL2004 and EsPhALL2010)","route":"/trials/esphall/","recorded":"enrolled 178","registry":"enrolment 49 (actual)","url":"https://clinicaltrials.gov/study/NCT00287105","severity":"medium"},{"check":"enrolled-vs-registry","id":"euramos-1","name":"EURAMOS-1","route":"/trials/euramos-1/","recorded":"enrolled 2260","registry":"enrolment 1334 (actual)","url":"https://clinicaltrials.gov/study/NCT00134030","severity":"medium"},{"check":"enrolled-vs-registry","id":"euro-ewing-2012","name":"Euro Ewing 2012","route":"/trials/euro-ewing-2012/","recorded":"enrolled 640","registry":"enrolment 907 (actual)","url":"https://clinicaltrials.gov/study/NCT00987636","severity":"medium"},{"check":"enrolled-vs-registry","id":"ev-303","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/","recorded":"enrolled 344","registry":"enrolment 595 (actual)","url":"https://clinicaltrials.gov/study/NCT03924895","severity":"medium"},{"check":"enrolled-vs-registry","id":"evera","name":"evERA","route":"/trials/evera/","recorded":"enrolled 320","registry":"enrolment 373 (actual)","url":"https://clinicaltrials.gov/study/NCT05306340","severity":"medium"},{"check":"enrolled-vs-registry","id":"nct05647122","name":"First in Human Study of AZD9592 in Solid Tumors","route":"/trials/nct05647122/","recorded":"enrolled 167","registry":"enrolment 190 (actual)","url":"https://clinicaltrials.gov/study/NCT05647122","severity":"medium"},{"check":"enrolled-vs-registry","id":"flaura","name":"FLAURA","route":"/trials/flaura/","recorded":"enrolled 556","registry":"enrolment 674 (actual)","url":"https://clinicaltrials.gov/study/NCT02296125","severity":"medium"},{"check":"enrolled-vs-registry","id":"fmt-pd1-refractory-melanoma-pitt","name":"FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)","route":"/trials/fmt-pd1-refractory-melanoma-pitt/","recorded":"enrolled 15","registry":"enrolment 20 (actual)","url":"https://clinicaltrials.gov/study/NCT03341143","severity":"medium"},{"check":"enrolled-vs-registry","id":"foenix-cca2","name":"FOENIX-CCA2","route":"/trials/foenix-cca2/","recorded":"enrolled 103","registry":"enrolment 407 (actual)","url":"https://clinicaltrials.gov/study/NCT02052778","severity":"medium"},{"check":"enrolled-vs-registry","id":"fort","name":"FoRT","route":"/trials/fort/","recorded":"enrolled 548","registry":"enrolment 614 (actual)","url":"https://clinicaltrials.gov/study/NCT00310167","severity":"medium"},{"check":"enrolled-vs-registry","id":"gog-0218-icon7","name":"GOG-0218 & ICON7 (bevacizumab)","route":"/trials/gog-0218-icon7/","recorded":"enrolled 3401","registry":"enrolment 1873 (actual)","url":"https://clinicaltrials.gov/study/NCT00262847","severity":"medium"},{"check":"enrolled-vs-registry","id":"hera-b31-n9831","name":"HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)","route":"/trials/hera-b31-n9831/","recorded":"enrolled 9000","registry":"enrolment 5099 (actual)","url":"https://clinicaltrials.gov/study/NCT00045032","severity":"medium"},{"check":"enrolled-vs-registry","id":"hero","name":"HERO","route":"/trials/hero/","recorded":"enrolled 930","registry":"enrolment 1134 (actual)","url":"https://clinicaltrials.gov/study/NCT03085095","severity":"medium"},{"check":"enrolled-vs-registry","id":"himalaya","name":"HIMALAYA","route":"/trials/himalaya/","recorded":"enrolled 1171","registry":"enrolment 1324 (actual)","url":"https://clinicaltrials.gov/study/NCT03298451","severity":"medium"},{"check":"enrolled-vs-registry","id":"horrad","name":"HORRAD","route":"/trials/horrad/","recorded":"enrolled 432","registry":"enrolment 59 (actual)","url":"https://clinicaltrials.gov/study/NCT01053676","severity":"medium"},{"check":"enrolled-vs-registry","id":"ignyte-eso","name":"IGNYTE-ESO","route":"/trials/ignyte-eso/","recorded":"enrolled 64","registry":"enrolment 103 (actual)","url":"https://clinicaltrials.gov/study/NCT03967223","severity":"medium"},{"check":"enrolled-vs-registry","id":"imbrave150","name":"IMbrave150","route":"/trials/imbrave150/","recorded":"enrolled 501","registry":"enrolment 558 (actual)","url":"https://clinicaltrials.gov/study/NCT03434379","severity":"medium"},{"check":"enrolled-vs-registry","id":"imforte","name":"IMforte","route":"/trials/imforte/","recorded":"enrolled 483","registry":"enrolment 660 (actual)","url":"https://clinicaltrials.gov/study/NCT05091567","severity":"medium"},{"check":"enrolled-vs-registry","id":"immagine-1","name":"iMMagine-1","route":"/trials/immagine-1/","recorded":"enrolled 117","registry":"enrolment 136 (actual)","url":"https://clinicaltrials.gov/study/NCT05396885","severity":"medium"},{"check":"enrolled-vs-registry","id":"impower133","name":"IMpower133","route":"/trials/impower133/","recorded":"enrolled 403","registry":"enrolment 503 (actual)","url":"https://clinicaltrials.gov/study/NCT02763579","severity":"medium"},{"check":"enrolled-vs-registry","id":"keynote-483","name":"IND.227 / KEYNOTE-483","route":"/trials/keynote-483/","recorded":"enrolled 440","registry":"enrolment 520 (actual)","url":"https://clinicaltrials.gov/study/NCT02784171","severity":"medium"},{"check":"enrolled-vs-registry","id":"ipatunity130","name":"IPATunity130","route":"/trials/ipatunity130/","recorded":"enrolled 255","registry":"enrolment 579 (actual)","url":"https://clinicaltrials.gov/study/NCT03337724","severity":"medium"},{"check":"enrolled-vs-registry","id":"isg-sts-1001","name":"ISG-STS 1001","route":"/trials/isg-sts-1001/","recorded":"enrolled 287","registry":"enrolment 550 (actual)","url":"https://clinicaltrials.gov/study/NCT01710176","severity":"medium"},{"check":"enrolled-vs-registry","id":"keynote-024-189","name":"KEYNOTE-024 & KEYNOTE-189","route":"/trials/keynote-024-189/","recorded":"enrolled 921","registry":"enrolment 305 (actual)","url":"https://clinicaltrials.gov/study/NCT02142738","severity":"medium"},{"check":"enrolled-vs-registry","id":"keynote-170","name":"KEYNOTE-170","route":"/trials/keynote-170/","recorded":"enrolled 53","registry":"enrolment 80 (actual)","url":"https://clinicaltrials.gov/study/NCT02576990","severity":"medium"},{"check":"enrolled-vs-registry","id":"lume-meso","name":"LUME-Meso","route":"/trials/lume-meso/","recorded":"enrolled 458","registry":"enrolment 545 (actual)","url":"https://clinicaltrials.gov/study/NCT01907100","severity":"medium"},{"check":"enrolled-vs-registry","id":"lummicar-1","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/","recorded":"enrolled 102","registry":"enrolment 121 (actual)","url":"https://clinicaltrials.gov/study/NCT03975907","severity":"medium"},{"check":"enrolled-vs-registry","id":"lurbinectedin-basket-sclc","name":"Lurbinectedin basket trial, small-cell lung cancer cohort","route":"/trials/lurbinectedin-basket-sclc/","recorded":"enrolled 105","registry":"enrolment 345 (actual)","url":"https://clinicaltrials.gov/study/NCT02454972","severity":"medium"},{"check":"enrolled-vs-registry","id":"magnetismm-3","name":"MagnetisMM-3","route":"/trials/magnetismm-3/","recorded":"enrolled 123","registry":"enrolment 187 (actual)","url":"https://clinicaltrials.gov/study/NCT04649359","severity":"medium"},{"check":"enrolled-vs-registry","id":"magnitude","name":"MAGNITUDE","route":"/trials/magnitude/","recorded":"enrolled 423","registry":"enrolment 765 (actual)","url":"https://clinicaltrials.gov/study/NCT03748641","severity":"medium"},{"check":"enrolled-vs-registry","id":"majestec-1","name":"MajesTEC-1","route":"/trials/majestec-1/","recorded":"enrolled 165","registry":"enrolment 194 (actual)","url":"https://clinicaltrials.gov/study/NCT04557098","severity":"medium"},{"check":"enrolled-vs-registry","id":"nmtrc003","name":"NMTRC003/003B (DFMO maintenance)","route":"/trials/nmtrc003/","recorded":"enrolled 105","registry":"enrolment 140 (actual)","url":"https://clinicaltrials.gov/study/NCT02395666","severity":"medium"},{"check":"enrolled-vs-registry","id":"nordicc","name":"NordICC (Nordic-European Initiative on Colorectal Cancer)","route":"/trials/nordicc/","recorded":"enrolled 84585","registry":"enrolment 95000 (actual)","url":"https://clinicaltrials.gov/study/NCT00883792","severity":"medium"},{"check":"enrolled-vs-registry","id":"nct06736717","name":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06736717/","recorded":"enrolled 21","registry":"enrolment 16 (actual)","url":"https://clinicaltrials.gov/study/NCT06736717","severity":"medium"},{"check":"enrolled-vs-registry","id":"oriole","name":"ORIOLE","route":"/trials/oriole/","recorded":"enrolled 54","registry":"enrolment 80 (actual)","url":"https://clinicaltrials.gov/study/NCT02680587","severity":"medium"},{"check":"enrolled-vs-registry","id":"pace-b","name":"PACE-B","route":"/trials/pace-b/","recorded":"enrolled 874","registry":"enrolment 2205 (actual)","url":"https://clinicaltrials.gov/study/NCT01584258","severity":"medium"},{"check":"enrolled-vs-registry","id":"pakt","name":"PAKT","route":"/trials/pakt/","recorded":"enrolled 140","registry":"enrolment 71 (actual)","url":"https://clinicaltrials.gov/study/NCT02423603","severity":"medium"},{"check":"enrolled-vs-registry","id":"pallas-penelope-b","name":"PALLAS & PENELOPE-B","route":"/trials/pallas-penelope-b/","recorded":"enrolled 6862","registry":"enrolment 5796 (actual)","url":"https://clinicaltrials.gov/study/NCT02513394","severity":"medium"},{"check":"enrolled-vs-registry","id":"polarix","name":"POLARIX","route":"/trials/polarix/","recorded":"enrolled 879","registry":"enrolment 1000 (actual)","url":"https://clinicaltrials.gov/study/NCT03274492","severity":"medium"},{"check":"enrolled-vs-registry","id":"pop-rt","name":"POP-RT","route":"/trials/pop-rt/","recorded":"enrolled 224","registry":"enrolment 761 (actual)","url":"https://clinicaltrials.gov/study/NCT01952223","severity":"medium"},{"check":"enrolled-vs-registry","id":"profile-1001-ros1","name":"PROFILE 1001 ROS1 expansion cohort","route":"/trials/profile-1001-ros1/","recorded":"enrolled 50","registry":"enrolment 596 (actual)","url":"https://clinicaltrials.gov/study/NCT00585195","severity":"medium"},{"check":"enrolled-vs-registry","id":"propel","name":"PROpel","route":"/trials/propel/","recorded":"enrolled 796","registry":"enrolment 895 (actual)","url":"https://clinicaltrials.gov/study/NCT03732820","severity":"medium"},{"check":"enrolled-vs-registry","id":"protect","name":"ProtecT","route":"/trials/protect/","recorded":"enrolled 1643","registry":"enrolment 82849 (actual)","url":"https://clinicaltrials.gov/study/NCT02044172","severity":"medium"},{"check":"enrolled-vs-registry","id":"psma-prerp","name":"PSMA-PreRP","route":"/trials/psma-prerp/","recorded":"enrolled 764","registry":"enrolment 400 (actual)","url":"https://clinicaltrials.gov/study/NCT03368547","severity":"medium"},{"check":"enrolled-vs-registry","id":"radiant-3-4","name":"RADIANT-3 and RADIANT-4","route":"/trials/radiant-3-4/","recorded":"enrolled 712","registry":"enrolment 410 (actual)","url":"https://clinicaltrials.gov/study/NCT00510068","severity":"medium"},{"check":"enrolled-vs-registry","id":"radicals-rt","name":"RADICALS-RT","route":"/trials/radicals-rt/","recorded":"enrolled 1396","registry":"enrolment 4236 (actual)","url":"https://clinicaltrials.gov/study/NCT00541047","severity":"medium"},{"check":"enrolled-vs-registry","id":"ready-dasatinib","name":"READY","route":"/trials/ready-dasatinib/","recorded":"enrolled 1522","registry":"enrolment 1930 (actual)","url":"https://clinicaltrials.gov/study/NCT00744497","severity":"medium"},{"check":"enrolled-vs-registry","id":"roar-atc","name":"ROAR (anaplastic thyroid cancer cohort)","route":"/trials/roar-atc/","recorded":"enrolled 36","registry":"enrolment 206 (actual)","url":"https://clinicaltrials.gov/study/NCT02034110","severity":"medium"},{"check":"enrolled-vs-registry","id":"romana-1-2","name":"ROMANA 1 and ROMANA 2","route":"/trials/romana-1-2/","recorded":"enrolled 979","registry":"enrolment 484 (actual)","url":"https://clinicaltrials.gov/study/NCT01387269","severity":"medium"},{"check":"enrolled-vs-registry","id":"ruby","name":"RUBY / ENGOT-EN6 / GOG-3031","route":"/trials/ruby/","recorded":"enrolled 494","registry":"enrolment 785 (actual)","url":"https://clinicaltrials.gov/study/NCT03981796","severity":"medium"},{"check":"enrolled-vs-registry","id":"sanet","name":"SANET-ep and SANET-p","route":"/trials/sanet/","recorded":"enrolled 369","registry":"enrolment 219 (actual)","url":"https://clinicaltrials.gov/study/NCT02588170","severity":"medium"},{"check":"enrolled-vs-registry","id":"sano","name":"SANO","route":"/trials/sano/","recorded":"enrolled 309","registry":"enrolment 776 (actual)","url":"https://clinicaltrials.gov/study/NCT05953181","severity":"medium"},{"check":"enrolled-vs-registry","id":"soft-text","name":"SOFT & TEXT","route":"/trials/soft-text/","recorded":"enrolled 5738","registry":"enrolment 3066 (actual)","url":"https://clinicaltrials.gov/study/NCT00066690","severity":"medium"},{"check":"enrolled-vs-registry","id":"solo-1","name":"SOLO-1","route":"/trials/solo-1/","recorded":"enrolled 391","registry":"enrolment 450 (actual)","url":"https://clinicaltrials.gov/study/NCT01844986","severity":"medium"},{"check":"enrolled-vs-registry","id":"nct05673057","name":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct05673057/","recorded":"enrolled 249","registry":"enrolment 80 (actual)","url":"https://clinicaltrials.gov/study/NCT05673057","severity":"medium"},{"check":"enrolled-vs-registry","id":"nct04626518","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","route":"/trials/nct04626518/","recorded":"enrolled 370","registry":"enrolment 263 (actual)","url":"https://clinicaltrials.gov/study/NCT04626518","severity":"medium"},{"check":"enrolled-vs-registry","id":"swog-9346","name":"SWOG 9346 (intermittent androgen deprivation)","route":"/trials/swog-9346/","recorded":"enrolled 1535","registry":"enrolment 3040 (actual)","url":"https://clinicaltrials.gov/study/NCT00002651","severity":"medium"},{"check":"enrolled-vs-registry","id":"tadpole","name":"TADPOLE (CDRB436G2201)","route":"/trials/tadpole/","recorded":"enrolled 110","registry":"enrolment 151 (actual)","url":"https://clinicaltrials.gov/study/NCT02684058","severity":"medium"},{"check":"enrolled-vs-registry","id":"talapro-2","name":"TALAPRO-2","route":"/trials/talapro-2/","recorded":"enrolled 805","registry":"enrolment 1054 (actual)","url":"https://clinicaltrials.gov/study/NCT03395197","severity":"medium"},{"check":"enrolled-vs-registry","id":"targit-a","name":"TARGIT-A (targeted intraoperative radiotherapy)","route":"/trials/targit-a/","recorded":"enrolled 2298","registry":"enrolment 3451 (actual)","url":"https://clinicaltrials.gov/study/NCT00983684","severity":"medium"},{"check":"enrolled-vs-registry","id":"thor","name":"THOR","route":"/trials/thor/","recorded":"enrolled 266","registry":"enrolment 629 (actual)","url":"https://clinicaltrials.gov/study/NCT03390504","severity":"medium"},{"check":"enrolled-vs-registry","id":"topaz-1","name":"TOPAZ-1","route":"/trials/topaz-1/","recorded":"enrolled 685","registry":"enrolment 810 (actual)","url":"https://clinicaltrials.gov/study/NCT03875235","severity":"medium"},{"check":"enrolled-vs-registry","id":"tracerx","name":"TRACERx","route":"/trials/tracerx/","recorded":"enrolled 421","registry":"enrolment 814 (actual)","url":"https://clinicaltrials.gov/study/NCT01888601","severity":"medium"},{"check":"enrolled-vs-registry","id":"transcend","name":"TRANSCEND","route":"/trials/transcend/","recorded":"enrolled 120","registry":"enrolment 143 (actual)","url":"https://clinicaltrials.gov/study/NCT05774756","severity":"medium"},{"check":"enrolled-vs-registry","id":"tumorapa","name":"TUMORAPA (switching from a calcineurin inhibitor to sirolimus after a transplant skin cancer)","route":"/trials/tumorapa/","recorded":"enrolled 120","registry":"enrolment 77 (actual)","url":"https://clinicaltrials.gov/study/NCT00133887","severity":"medium"},{"check":"enrolled-vs-registry","id":"ux023t-cl201","name":"UX023T-CL201","route":"/trials/ux023t-cl201/","recorded":"enrolled 14","registry":"enrolment 17 (actual)","url":"https://clinicaltrials.gov/study/NCT02304367","severity":"medium"},{"check":"nct-title-mismatch","id":"admiral","name":"ADMIRAL","route":"/trials/admiral/","recorded":"NCT02421939: \"ADMIRAL\"","registry":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With","url":"https://clinicaltrials.gov/study/NCT02421939","severity":"medium"},{"check":"nct-title-mismatch","id":"attraction-2","name":"ATTRACTION-2","route":"/trials/attraction-2/","recorded":"NCT02267343: \"ATTRACTION-2\"","registry":"Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer","url":"https://clinicaltrials.gov/study/NCT02267343","severity":"medium"},{"check":"nct-title-mismatch","id":"decision-sorafenib","name":"DECISION","route":"/trials/decision-sorafenib/","recorded":"NCT00984282: \"DECISION\"","registry":"Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","url":"https://clinicaltrials.gov/study/NCT00984282","severity":"medium"},{"check":"nct-title-mismatch","id":"echelon-1","name":"ECHELON-1","route":"/trials/echelon-1/","recorded":"NCT01712490: \"ECHELON-1\"","registry":"A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma","url":"https://clinicaltrials.gov/study/NCT01712490","severity":"medium"},{"check":"nct-title-mismatch","id":"empower-cscc-1","name":"EMPOWER-CSCC-1","route":"/trials/empower-cscc-1/","recorded":"NCT02760498: \"EMPOWER-CSCC-1\"","registry":"Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT02760498","severity":"medium"},{"check":"nct-title-mismatch","id":"empower-lung-1","name":"EMPOWER-Lung 1","route":"/trials/empower-lung-1/","recorded":"NCT03088540: \"EMPOWER-Lung 1\"","registry":"Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer ","url":"https://clinicaltrials.gov/study/NCT03088540","severity":"medium"},{"check":"nct-title-mismatch","id":"escort-1st","name":"ESCORT-1st","route":"/trials/escort-1st/","recorded":"NCT03691090: \"ESCORT-1st\"","registry":"Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer","url":"https://clinicaltrials.gov/study/NCT03691090","severity":"medium"},{"check":"nct-title-mismatch","id":"foenix-cca2","name":"FOENIX-CCA2","route":"/trials/foenix-cca2/","recorded":"NCT02052778: \"FOENIX-CCA2\"","registry":"A Study of TAS-120 in Patients With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT02052778","severity":"medium"},{"check":"nct-title-mismatch","id":"horrad","name":"HORRAD","route":"/trials/horrad/","recorded":"NCT01053676: \"HORRAD\"","registry":"Bioequivalence Study of BAY77-1931 Granule","url":"https://clinicaltrials.gov/study/NCT01053676","severity":"medium"},{"check":"nct-title-mismatch","id":"i-spy-2","name":"I-SPY 2","route":"/trials/i-spy-2/","recorded":"NCT01042379: \"I-SPY 2\"","registry":"I-SPY: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","url":"https://clinicaltrials.gov/study/NCT01042379","severity":"medium"},{"check":"nct-title-mismatch","id":"i-spy-2-2","name":"I-SPY 2.2","route":"/trials/i-spy-2-2/","recorded":"NCT01042379: \"I-SPY 2.2\"","registry":"I-SPY: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","url":"https://clinicaltrials.gov/study/NCT01042379","severity":"medium"},{"check":"nct-title-mismatch","id":"ion-trial","name":"IoN","route":"/trials/ion-trial/","recorded":"NCT01398085: \"IoN\"","registry":"IoN: IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients","url":"https://clinicaltrials.gov/study/NCT01398085","severity":"medium"},{"check":"nct-title-mismatch","id":"opra","name":"OPRA","route":"/trials/opra/","recorded":"NCT02008656: \"OPRA\"","registry":"Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiatio","url":"https://clinicaltrials.gov/study/NCT02008656","severity":"medium"},{"check":"nct-title-mismatch","id":"pace-b","name":"PACE-B","route":"/trials/pace-b/","recorded":"NCT01584258: \"PACE-B\"","registry":"PACE: Prostate Advances in Comparative Evidence","url":"https://clinicaltrials.gov/study/NCT01584258","severity":"medium"},{"check":"nct-title-mismatch","id":"pop-rt","name":"POP-RT","route":"/trials/pop-rt/","recorded":"NCT01952223: \"POP-RT\"","registry":"PEACE2: A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse","url":"https://clinicaltrials.gov/study/NCT01952223","severity":"medium"},{"check":"nct-title-mismatch","id":"prodige-7","name":"PRODIGE 7","route":"/trials/prodige-7/","recorded":"NCT00769405: \"PRODIGE 7\"","registry":"Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peri","url":"https://clinicaltrials.gov/study/NCT00769405","severity":"medium"},{"check":"nct-title-mismatch","id":"rathl","name":"RATHL","route":"/trials/rathl/","recorded":"NCT00678327: \"RATHL\"","registry":"Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Sta","url":"https://clinicaltrials.gov/study/NCT00678327","severity":"medium"},{"check":"nct-title-mismatch","id":"zeta","name":"ZETA","route":"/trials/zeta/","recorded":"NCT00410761: \"ZETA\"","registry":"An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer","url":"https://clinicaltrials.gov/study/NCT00410761","severity":"medium"},{"check":"openfda-label-but-not-approved","id":"aspirin","name":"Aspirin","route":"/drugs/aspirin/","recorded":"status established, no US approval recorded","registry":"openFDA has a label for \"Aspirin\"","url":"https://open.fda.gov/apis/drug/label/","severity":"medium"},{"check":"openfda-label-but-not-approved","id":"danazol","name":"Danazol","route":"/drugs/danazol/","recorded":"status established, no US approval recorded","registry":"openFDA has a label for \"Danazol\"","url":"https://open.fda.gov/apis/drug/label/","severity":"medium"},{"check":"openfda-label-but-not-approved","id":"givinostat","name":"Givinostat","route":"/drugs/givinostat/","recorded":"status phase-3, no US approval recorded","registry":"openFDA has a label for \"Givinostat\"","url":"https://open.fda.gov/apis/drug/label/","severity":"medium"},{"check":"openfda-label-but-not-approved","id":"ivermectin","name":"Ivermectin","route":"/drugs/ivermectin/","recorded":"status phase-2, no US approval recorded","registry":"openFDA has a label for \"Ivermectin\"","url":"https://open.fda.gov/apis/drug/label/","severity":"medium"},{"check":"openfda-label-but-not-approved","id":"metyrapone","name":"Metyrapone","route":"/drugs/metyrapone/","recorded":"status established, no US approval recorded","registry":"openFDA has a label for \"Metyrapone\"","url":"https://open.fda.gov/apis/drug/label/","severity":"medium"},{"check":"openfda-label-but-not-approved","id":"mifepristone","name":"Mifepristone","route":"/drugs/mifepristone/","recorded":"status negative, no US approval recorded","registry":"openFDA has a label for \"Mifepristone\"","url":"https://open.fda.gov/apis/drug/label/","severity":"medium"},{"check":"openfda-label-but-not-approved","id":"nicotinamide","name":"Nicotinamide","route":"/drugs/nicotinamide/","recorded":"status established, no US approval recorded","registry":"openFDA has a label for \"Nicotinamide\"","url":"https://open.fda.gov/apis/drug/label/","severity":"medium"},{"check":"openfda-label-but-not-approved","id":"pancrelipase","name":"Pancrelipase (pancreatic enzyme replacement therapy)","route":"/drugs/pancrelipase/","recorded":"status established, no US approval recorded","registry":"openFDA has a label for \"Pancrelipase\"","url":"https://open.fda.gov/apis/drug/label/","severity":"medium"},{"check":"primary-completion-passed","id":"nct04996875","name":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis","route":"/trials/nct04996875/","recorded":"recruiting","registry":"primary completion 2025-09-19 (actual)","url":"https://clinicaltrials.gov/study/NCT04996875","severity":"medium"},{"check":"primary-completion-passed","id":"nct05208047","name":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors","route":"/trials/nct05208047/","recorded":"recruiting","registry":"primary completion 2025-09-30 (actual)","url":"https://clinicaltrials.gov/study/NCT05208047","severity":"medium"},{"check":"primary-completion-passed","id":"nct05667506","name":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","route":"/trials/nct05667506/","recorded":"recruiting","registry":"primary completion 2025-05-30 (actual)","url":"https://clinicaltrials.gov/study/NCT05667506","severity":"medium"},{"check":"primary-completion-passed","id":"nct06703398","name":"A Study of GC101 TIL in Advanced Melanoma","route":"/trials/nct06703398/","recorded":"recruiting","registry":"primary completion 2026-05-12 (actual)","url":"https://clinicaltrials.gov/study/NCT06703398","severity":"medium"},{"check":"primary-completion-passed","id":"nct05020236","name":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","route":"/trials/nct05020236/","recorded":"recruiting","registry":"primary completion 2026-02-26 (actual)","url":"https://clinicaltrials.gov/study/NCT05020236","severity":"medium"},{"check":"primary-completion-passed","id":"nct00722228","name":"Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors","route":"/trials/nct00722228/","recorded":"recruiting","registry":"primary completion 2025-03 (actual)","url":"https://clinicaltrials.gov/study/NCT00722228","severity":"medium"},{"check":"primary-completion-passed","id":"nct04684147","name":"Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia","route":"/trials/nct04684147/","recorded":"recruiting","registry":"primary completion 2022-09-22 (actual)","url":"https://clinicaltrials.gov/study/NCT04684147","severity":"medium"},{"check":"primary-completion-passed","id":"nct06778382","name":"Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.","route":"/trials/nct06778382/","recorded":"recruiting","registry":"primary completion 2025-11-01 (actual)","url":"https://clinicaltrials.gov/study/NCT06778382","severity":"medium"},{"check":"primary-completion-passed","id":"nct05640791","name":"Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer","route":"/trials/nct05640791/","recorded":"recruiting","registry":"primary completion 2023-12-31 (actual)","url":"https://clinicaltrials.gov/study/NCT05640791","severity":"medium"},{"check":"primary-completion-passed","id":"nct04844866","name":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","route":"/trials/nct04844866/","recorded":"recruiting","registry":"primary completion 2025-01-15 (actual)","url":"https://clinicaltrials.gov/study/NCT04844866","severity":"medium"},{"check":"primary-completion-passed","id":"nct06484153","name":"Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma","route":"/trials/nct06484153/","recorded":"recruiting","registry":"primary completion 2026-07-22 (actual)","url":"https://clinicaltrials.gov/study/NCT06484153","severity":"medium"},{"check":"primary-completion-passed","id":"nct03364530","name":"Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma","route":"/trials/nct03364530/","recorded":"recruiting","registry":"primary completion 2025-10-21 (actual)","url":"https://clinicaltrials.gov/study/NCT03364530","severity":"medium"},{"check":"primary-completion-passed","id":"nct06435260","name":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06435260/","recorded":"recruiting","registry":"primary completion 2025-06-01 (actual)","url":"https://clinicaltrials.gov/study/NCT06435260","severity":"medium"},{"check":"primary-completion-passed","id":"nct05027776","name":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","route":"/trials/nct05027776/","recorded":"recruiting","registry":"primary completion 2023-11-22 (actual)","url":"https://clinicaltrials.gov/study/NCT05027776","severity":"medium"},{"check":"primary-completion-passed","id":"nct06349590","name":"Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery","route":"/trials/nct06349590/","recorded":"recruiting","registry":"primary completion 2026-04-06 (actual)","url":"https://clinicaltrials.gov/study/NCT06349590","severity":"medium"},{"check":"primary-completion-passed","id":"nct04084496","name":"mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients","route":"/trials/nct04084496/","recorded":"recruiting","registry":"primary completion 2024-12-31 (actual)","url":"https://clinicaltrials.gov/study/NCT04084496","severity":"medium"},{"check":"primary-completion-passed","id":"nct04110301","name":"MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)","route":"/trials/nct04110301/","recorded":"recruiting","registry":"primary completion 2024-01-09 (actual)","url":"https://clinicaltrials.gov/study/NCT04110301","severity":"medium"},{"check":"primary-completion-passed","id":"nct06514508","name":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","route":"/trials/nct06514508/","recorded":"recruiting","registry":"primary completion 2026-09-11 (actual)","url":"https://clinicaltrials.gov/study/NCT06514508","severity":"medium"},{"check":"primary-completion-passed","id":"nct05972655","name":"Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer","route":"/trials/nct05972655/","recorded":"recruiting","registry":"primary completion 2024-08-20 (actual)","url":"https://clinicaltrials.gov/study/NCT05972655","severity":"medium"},{"check":"primary-completion-passed","id":"nct06736717","name":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06736717/","recorded":"recruiting","registry":"primary completion 2026-07-16 (actual)","url":"https://clinicaltrials.gov/study/NCT06736717","severity":"medium"},{"check":"primary-completion-passed","id":"nct04643418","name":"Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors","route":"/trials/nct04643418/","recorded":"recruiting","registry":"primary completion 2025-03-31 (actual)","url":"https://clinicaltrials.gov/study/NCT04643418","severity":"medium"},{"check":"primary-completion-passed","id":"nct04586478","name":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","route":"/trials/nct04586478/","recorded":"recruiting","registry":"primary completion 2024-03-30 (actual)","url":"https://clinicaltrials.gov/study/NCT04586478","severity":"medium"},{"check":"primary-completion-passed","id":"nct07448077","name":"Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC","route":"/trials/nct07448077/","recorded":"recruiting","registry":"primary completion 2026-03-01 (actual)","url":"https://clinicaltrials.gov/study/NCT07448077","severity":"medium"},{"check":"primary-completion-passed","id":"nct06050317","name":"Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer","route":"/trials/nct06050317/","recorded":"recruiting","registry":"primary completion 2025-08-18 (actual)","url":"https://clinicaltrials.gov/study/NCT06050317","severity":"medium"},{"check":"primary-completion-passed","id":"nct06754085","name":"Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","route":"/trials/nct06754085/","recorded":"recruiting","registry":"primary completion 2026-06-11 (actual)","url":"https://clinicaltrials.gov/study/NCT06754085","severity":"medium"},{"check":"primary-completion-passed","id":"nct04494503","name":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct04494503/","recorded":"recruiting","registry":"primary completion 2024-10-20 (actual)","url":"https://clinicaltrials.gov/study/NCT04494503","severity":"medium"},{"check":"primary-completion-passed","id":"nct06297226","name":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06297226/","recorded":"recruiting","registry":"primary completion 2026-07-31 (actual)","url":"https://clinicaltrials.gov/study/NCT06297226","severity":"medium"},{"check":"primary-completion-passed","id":"nct03874026","name":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","route":"/trials/nct03874026/","recorded":"recruiting","registry":"primary completion 2023-05-19 (actual)","url":"https://clinicaltrials.gov/study/NCT03874026","severity":"medium"},{"check":"primary-completion-passed","id":"nct06909877","name":"Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06909877/","recorded":"recruiting","registry":"primary completion 2025-10-31 (actual)","url":"https://clinicaltrials.gov/study/NCT06909877","severity":"medium"},{"check":"primary-completion-passed","id":"nct05218889","name":"Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer","route":"/trials/nct05218889/","recorded":"recruiting","registry":"primary completion 2024-12-16 (actual)","url":"https://clinicaltrials.gov/study/NCT05218889","severity":"medium"},{"check":"primary-completion-passed","id":"nct05555888","name":"The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer","route":"/trials/nct05555888/","recorded":"recruiting","registry":"primary completion 2024-03-12 (actual)","url":"https://clinicaltrials.gov/study/NCT05555888","severity":"medium"},{"check":"primary-completion-passed","id":"nct05624138","name":"The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy","route":"/trials/nct05624138/","recorded":"recruiting","registry":"primary completion 2024-04-04 (actual)","url":"https://clinicaltrials.gov/study/NCT05624138","severity":"medium"},{"check":"primary-completion-passed","id":"nct06756269","name":"To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","route":"/trials/nct06756269/","recorded":"recruiting","registry":"primary completion 2025-10-30 (actual)","url":"https://clinicaltrials.gov/study/NCT06756269","severity":"medium"},{"check":"primary-completion-passed","id":"nct05948813","name":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","route":"/trials/nct05948813/","recorded":"recruiting","registry":"primary completion 2025-12-15 (actual)","url":"https://clinicaltrials.gov/study/NCT05948813","severity":"medium"},{"check":"trial-phase-vs-registry","id":"nct06614192","name":"A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer","route":"/trials/nct06614192/","recorded":"phase 3","registry":"PHASE2","url":"https://clinicaltrials.gov/study/NCT06614192","severity":"medium"},{"check":"trial-phase-vs-registry","id":"beamion-lung-1","name":"Beamion LUNG-1","route":"/trials/beamion-lung-1/","recorded":"phase 1/2","registry":"PHASE1","url":"https://clinicaltrials.gov/study/NCT04886804","severity":"medium"},{"check":"trial-phase-vs-registry","id":"card","name":"CARD","route":"/trials/card/","recorded":"phase 3","registry":"PHASE4","url":"https://clinicaltrials.gov/study/NCT02485691","severity":"medium"},{"check":"trial-phase-vs-registry","id":"horrad","name":"HORRAD","route":"/trials/horrad/","recorded":"phase 3","registry":"PHASE1","url":"https://clinicaltrials.gov/study/NCT01053676","severity":"medium"},{"check":"trial-phase-vs-registry","id":"majestec-1","name":"MajesTEC-1","route":"/trials/majestec-1/","recorded":"phase 1/2","registry":"PHASE2","url":"https://clinicaltrials.gov/study/NCT04557098","severity":"medium"},{"check":"trial-phase-vs-registry","id":"monumental-1","name":"MonumenTAL-1","route":"/trials/monumental-1/","recorded":"phase 1/2","registry":"PHASE2","url":"https://clinicaltrials.gov/study/NCT04634552","severity":"medium"},{"check":"trial-phase-vs-registry","id":"norpact-1","name":"NORPACT-1","route":"/trials/norpact-1/","recorded":"phase 2","registry":"PHASE2/PHASE3","url":"https://clinicaltrials.gov/study/NCT02919787","severity":"medium"},{"check":"trial-phase-vs-registry","id":"panfire-2","name":"PANFIRE-2","route":"/trials/panfire-2/","recorded":"phase 2","registry":"PHASE1/PHASE2","url":"https://clinicaltrials.gov/study/NCT01939665","severity":"medium"},{"check":"trial-phase-vs-registry","id":"patch-transdermal-oestradiol","name":"PATCH (Prostate Adenocarcinoma Transcutaneous Hormone)","route":"/trials/patch-transdermal-oestradiol/","recorded":"phase 2/3","registry":"PHASE3","url":"https://clinicaltrials.gov/study/NCT00303784","severity":"medium"},{"check":"trial-phase-vs-registry","id":"pathos","name":"PATHOS","route":"/trials/pathos/","recorded":"phase 2/3","registry":"PHASE3","url":"https://clinicaltrials.gov/study/NCT02215265","severity":"medium"},{"check":"trial-phase-vs-registry","id":"prodige-4-accord-11","name":"PRODIGE 4 / ACCORD 11","route":"/trials/prodige-4-accord-11/","recorded":"phase 3","registry":"PHASE2/PHASE3","url":"https://clinicaltrials.gov/study/NCT00112658","severity":"medium"},{"check":"trial-phase-vs-registry","id":"nct05673057","name":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct05673057/","recorded":"phase 1/2","registry":"PHASE1","url":"https://clinicaltrials.gov/study/NCT05673057","severity":"medium"},{"check":"trial-status-vs-registry","id":"alkove-1","name":"ALKOVE-1","route":"/trials/alkove-1/","recorded":"positive","registry":"RECRUITING","url":"https://clinicaltrials.gov/study/NCT05384626","severity":"medium"},{"check":"trial-status-vs-registry","id":"a071401","name":"Alliance A071401","route":"/trials/a071401/","recorded":"positive","registry":"RECRUITING","url":"https://clinicaltrials.gov/study/NCT02523014","severity":"medium"},{"check":"trial-status-vs-registry","id":"augment-101","name":"AUGMENT-101","route":"/trials/augment-101/","recorded":"positive","registry":"RECRUITING","url":"https://clinicaltrials.gov/study/NCT04065399","severity":"medium"},{"check":"trial-status-vs-registry","id":"nct07670312","name":"Evaluation of XYA02 in Patients With Advanced Solid Tumors","route":"/trials/nct07670312/","recorded":"planned","registry":"RECRUITING","url":"https://clinicaltrials.gov/study/NCT07670312","severity":"medium"},{"check":"trial-status-vs-registry","id":"firefly-1","name":"FIREFLY-1","route":"/trials/firefly-1/","recorded":"positive","registry":"RECRUITING","url":"https://clinicaltrials.gov/study/NCT04775485","severity":"medium"},{"check":"trial-status-vs-registry","id":"harmoni-3","name":"HARMONi-3","route":"/trials/harmoni-3/","recorded":"mixed","registry":"RECRUITING","url":"https://clinicaltrials.gov/study/NCT05899608","severity":"medium"},{"check":"trial-status-vs-registry","id":"linker-mm1","name":"LINKER-MM1","route":"/trials/linker-mm1/","recorded":"positive","registry":"RECRUITING","url":"https://clinicaltrials.gov/study/NCT03761108","severity":"medium"},{"check":"trial-status-vs-registry","id":"monumental-1","name":"MonumenTAL-1","route":"/trials/monumental-1/","recorded":"positive","registry":"RECRUITING","url":"https://clinicaltrials.gov/study/NCT04634552","severity":"medium"},{"check":"trial-status-vs-registry","id":"niche-2","name":"NICHE-2","route":"/trials/niche-2/","recorded":"positive","registry":"RECRUITING","url":"https://clinicaltrials.gov/study/NCT03026140","severity":"medium"},{"check":"trial-status-vs-registry","id":"partner","name":"PARTNER","route":"/trials/partner/","recorded":"positive","registry":"RECRUITING","url":"https://clinicaltrials.gov/study/NCT03150576","severity":"medium"},{"check":"trial-status-vs-registry","id":"nct07271355","name":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,","route":"/trials/nct07271355/","recorded":"planned","registry":"RECRUITING","url":"https://clinicaltrials.gov/study/NCT07271355","severity":"medium"},{"check":"trial-status-vs-registry","id":"hr-nbl1","name":"SIOPEN HR-NBL1","route":"/trials/hr-nbl1/","recorded":"mixed","registry":"RECRUITING","url":"https://clinicaltrials.gov/study/NCT01704716","severity":"medium"},{"check":"trial-status-vs-registry","id":"soho-01","name":"SOHO-01","route":"/trials/soho-01/","recorded":"positive","registry":"RECRUITING","url":"https://clinicaltrials.gov/study/NCT05099172","severity":"medium"},{"check":"trial-status-vs-registry","id":"nct06754085","name":"Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","route":"/trials/nct06754085/","recorded":"recruiting","registry":"COMPLETED","url":"https://clinicaltrials.gov/study/NCT06754085","severity":"medium"},{"check":"enrolled-vs-registry","id":"nct06929624","name":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","route":"/trials/nct06929624/","recorded":"enrolled 280","registry":"enrolment 282 (actual)","url":"https://clinicaltrials.gov/study/NCT06929624","severity":"low"},{"check":"enrolled-vs-registry","id":"nct07172802","name":"A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07172802/","recorded":"enrolled 76","registry":"enrolment 102 (estimated)","url":"https://clinicaltrials.gov/study/NCT07172802","severity":"low"},{"check":"enrolled-vs-registry","id":"nct07266441","name":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07266441/","recorded":"enrolled 157","registry":"enrolment 168 (actual)","url":"https://clinicaltrials.gov/study/NCT07266441","severity":"low"},{"check":"enrolled-vs-registry","id":"nct06855771","name":"A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)","route":"/trials/nct06855771/","recorded":"enrolled 130","registry":"enrolment 182 (estimated)","url":"https://clinicaltrials.gov/study/NCT06855771","severity":"low"},{"check":"enrolled-vs-registry","id":"nct05023980","name":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","route":"/trials/nct05023980/","recorded":"enrolled 309","registry":"enrolment 282 (actual)","url":"https://clinicaltrials.gov/study/NCT05023980","severity":"low"},{"check":"enrolled-vs-registry","id":"nct06660654","name":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","route":"/trials/nct06660654/","recorded":"enrolled 200","registry":"enrolment 335 (estimated)","url":"https://clinicaltrials.gov/study/NCT06660654","severity":"low"},{"check":"enrolled-vs-registry","id":"nct07183189","name":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","route":"/trials/nct07183189/","recorded":"enrolled 576","registry":"enrolment 582 (actual)","url":"https://clinicaltrials.gov/study/NCT07183189","severity":"low"},{"check":"enrolled-vs-registry","id":"nct07525206","name":"A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer","route":"/trials/nct07525206/","recorded":"enrolled 700","registry":"enrolment 990 (estimated)","url":"https://clinicaltrials.gov/study/NCT07525206","severity":"low"},{"check":"enrolled-vs-registry","id":"adiuvo","name":"ADIUVO","route":"/trials/adiuvo/","recorded":"enrolled 91","registry":"enrolment 200 (estimated)","url":"https://clinicaltrials.gov/study/NCT00777244","severity":"low"},{"check":"enrolled-vs-registry","id":"admec-o","name":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)","route":"/trials/admec-o/","recorded":"enrolled 179","registry":"enrolment 180 (actual)","url":"https://clinicaltrials.gov/study/NCT02196961","severity":"low"},{"check":"enrolled-vs-registry","id":"affinity-custirsen","name":"AFFINITY","route":"/trials/affinity-custirsen/","recorded":"enrolled 635","registry":"enrolment 630 (actual)","url":"https://clinicaltrials.gov/study/NCT01578655","severity":"low"},{"check":"enrolled-vs-registry","id":"ukallr3","name":"ALL R3 (UKALLR3)","route":"/trials/ukallr3/","recorded":"enrolled 216","registry":"enrolment 470 (estimated)","url":"https://clinicaltrials.gov/study/NCT00967057","severity":"low"},{"check":"enrolled-vs-registry","id":"a071401","name":"Alliance A071401","route":"/trials/a071401/","recorded":"enrolled 36","registry":"enrolment 124 (estimated)","url":"https://clinicaltrials.gov/study/NCT02523014","severity":"low"},{"check":"enrolled-vs-registry","id":"aphinity","name":"APHINITY","route":"/trials/aphinity/","recorded":"enrolled 4805","registry":"enrolment 4804 (actual)","url":"https://clinicaltrials.gov/study/NCT01358877","severity":"low"},{"check":"enrolled-vs-registry","id":"augment-101","name":"AUGMENT-101","route":"/trials/augment-101/","recorded":"enrolled 94","registry":"enrolment 447 (estimated)","url":"https://clinicaltrials.gov/study/NCT04065399","severity":"low"},{"check":"enrolled-vs-registry","id":"aura3","name":"AURA3","route":"/trials/aura3/","recorded":"enrolled 419","registry":"enrolment 421 (actual)","url":"https://clinicaltrials.gov/study/NCT02151981","severity":"low"},{"check":"enrolled-vs-registry","id":"beacon-crc","name":"BEACON CRC","route":"/trials/beacon-crc/","recorded":"enrolled 665","registry":"enrolment 702 (actual)","url":"https://clinicaltrials.gov/study/NCT02928224","severity":"low"},{"check":"enrolled-vs-registry","id":"nct04752826","name":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","route":"/trials/nct04752826/","recorded":"enrolled 176","registry":"enrolment 250 (estimated)","url":"https://clinicaltrials.gov/study/NCT04752826","severity":"low"},{"check":"enrolled-vs-registry","id":"bond-003","name":"BOND-003","route":"/trials/bond-003/","recorded":"enrolled 110","registry":"enrolment 190 (estimated)","url":"https://clinicaltrials.gov/study/NCT04452591","severity":"low"},{"check":"enrolled-vs-registry","id":"bwel","name":"BWEL (Breast Cancer Weight Loss, Alliance A011401)","route":"/trials/bwel/","recorded":"enrolled 3181","registry":"enrolment 3177 (actual)","url":"https://clinicaltrials.gov/study/NCT02750826","severity":"low"},{"check":"enrolled-vs-registry","id":"aall1731","name":"COG AALL1731","route":"/trials/aall1731/","recorded":"enrolled 1440","registry":"enrolment 6720 (estimated)","url":"https://clinicaltrials.gov/study/NCT03914625","severity":"low"},{"check":"enrolled-vs-registry","id":"conko-007","name":"CONKO-007","route":"/trials/conko-007/","recorded":"enrolled 336","registry":"enrolment 830 (estimated)","url":"https://clinicaltrials.gov/study/NCT01827553","severity":"low"},{"check":"enrolled-vs-registry","id":"crossfire","name":"CROSSFIRE","route":"/trials/crossfire/","recorded":"enrolled 68","registry":"enrolment 74 (actual)","url":"https://clinicaltrials.gov/study/NCT02791503","severity":"low"},{"check":"enrolled-vs-registry","id":"crystal-fire3","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","recorded":"enrolled 1198","registry":"enrolment 1221 (actual)","url":"https://clinicaltrials.gov/study/NCT00154102","severity":"low"},{"check":"enrolled-vs-registry","id":"dart-01-05-gicor","name":"DART 01/05 GICOR","route":"/trials/dart-01-05-gicor/","recorded":"enrolled 355","registry":"enrolment 362 (actual)","url":"https://clinicaltrials.gov/study/NCT02175212","severity":"low"},{"check":"enrolled-vs-registry","id":"eliana","name":"ELIANA","route":"/trials/eliana/","recorded":"enrolled 79","registry":"enrolment 80 (actual)","url":"https://clinicaltrials.gov/study/NCT02435849","severity":"low"},{"check":"enrolled-vs-registry","id":"empower-lung-1","name":"EMPOWER-Lung 1","route":"/trials/empower-lung-1/","recorded":"enrolled 710","registry":"enrolment 712 (actual)","url":"https://clinicaltrials.gov/study/NCT03088540","severity":"low"},{"check":"enrolled-vs-registry","id":"gd2-cart01","name":"GD2-CART01 (Bambino Gesù phase 1/2)","route":"/trials/gd2-cart01/","recorded":"enrolled 27","registry":"enrolment 42 (estimated)","url":"https://clinicaltrials.gov/study/NCT03373097","severity":"low"},{"check":"enrolled-vs-registry","id":"harmoni-3","name":"HARMONi-3","route":"/trials/harmoni-3/","recorded":"enrolled 1080","registry":"enrolment 1600 (estimated)","url":"https://clinicaltrials.gov/study/NCT05899608","severity":"low"},{"check":"enrolled-vs-registry","id":"nxc-201-mm","name":"HBI0101 (NXC-201) multiple myeloma phase 1","route":"/trials/nxc-201-mm/","recorded":"enrolled 20","registry":"enrolment 160 (estimated)","url":"https://clinicaltrials.gov/study/NCT04720313","severity":"low"},{"check":"enrolled-vs-registry","id":"insema","name":"INSEMA (Intergroup Sentinel Mamma)","route":"/trials/insema/","recorded":"enrolled 5502","registry":"enrolment 5505 (actual)","url":"https://clinicaltrials.gov/study/NCT02466737","severity":"low"},{"check":"enrolled-vs-registry","id":"interfant-06","name":"Interfant-06","route":"/trials/interfant-06/","recorded":"enrolled 651","registry":"enrolment 445 (estimated)","url":"https://clinicaltrials.gov/study/NCT00550992","severity":"low"},{"check":"enrolled-vs-registry","id":"istopmm","name":"iStopMM","route":"/trials/istopmm/","recorded":"enrolled 75422","registry":"enrolment 80761 (actual)","url":"https://clinicaltrials.gov/study/NCT03327597","severity":"low"},{"check":"enrolled-vs-registry","id":"komet-001","name":"KOMET-001","route":"/trials/komet-001/","recorded":"enrolled 112","registry":"enrolment 263 (estimated)","url":"https://clinicaltrials.gov/study/NCT04067336","severity":"low"},{"check":"enrolled-vs-registry","id":"lap07","name":"LAP07","route":"/trials/lap07/","recorded":"enrolled 449","registry":"enrolment 820 (estimated)","url":"https://clinicaltrials.gov/study/NCT00634725","severity":"low"},{"check":"enrolled-vs-registry","id":"legend-2","name":"LEGEND-2","route":"/trials/legend-2/","recorded":"enrolled 57","registry":"enrolment 100 (estimated)","url":"https://clinicaltrials.gov/study/NCT03090659","severity":"low"},{"check":"enrolled-vs-registry","id":"linker-mm1","name":"LINKER-MM1","route":"/trials/linker-mm1/","recorded":"enrolled 117","registry":"enrolment 387 (estimated)","url":"https://clinicaltrials.gov/study/NCT03761108","severity":"low"},{"check":"enrolled-vs-registry","id":"masai","name":"MASAI (Mammography Screening with Artificial Intelligence)","route":"/trials/masai/","recorded":"enrolled 105934","registry":"enrolment 100000 (actual)","url":"https://clinicaltrials.gov/study/NCT04838756","severity":"low"},{"check":"enrolled-vs-registry","id":"ielsg43","name":"MATRix/IELSG43","route":"/trials/ielsg43/","recorded":"enrolled 368","registry":"enrolment 250 (estimated)","url":"https://clinicaltrials.gov/study/NCT02531841","severity":"low"},{"check":"enrolled-vs-registry","id":"mntx-302","name":"MNTX 302","route":"/trials/mntx-302/","recorded":"enrolled 133","registry":"enrolment 134 (actual)","url":"https://clinicaltrials.gov/study/NCT00402038","severity":"low"},{"check":"enrolled-vs-registry","id":"monumental-1","name":"MonumenTAL-1","route":"/trials/monumental-1/","recorded":"enrolled 288","registry":"enrolment 510 (estimated)","url":"https://clinicaltrials.gov/study/NCT04634552","severity":"low"},{"check":"enrolled-vs-registry","id":"naxitamab-201","name":"Naxitamab Study 201","route":"/trials/naxitamab-201/","recorded":"enrolled 74","registry":"enrolment 122 (estimated)","url":"https://clinicaltrials.gov/study/NCT03363373","severity":"low"},{"check":"enrolled-vs-registry","id":"nhs-galleri","name":"NHS-Galleri","route":"/trials/nhs-galleri/","recorded":"enrolled 142250","registry":"enrolment 142318 (actual)","url":"https://clinicaltrials.gov/study/NCT05611632","severity":"low"},{"check":"enrolled-vs-registry","id":"niche-2","name":"NICHE-2","route":"/trials/niche-2/","recorded":"enrolled 115","registry":"enrolment 353 (estimated)","url":"https://clinicaltrials.gov/study/NCT03026140","severity":"low"},{"check":"enrolled-vs-registry","id":"nrg-gy018-keynote-868","name":"NRG-GY018 / KEYNOTE-868","route":"/trials/nrg-gy018-keynote-868/","recorded":"enrolled 816","registry":"enrolment 813 (actual)","url":"https://clinicaltrials.gov/study/NCT03914612","severity":"low"},{"check":"enrolled-vs-registry","id":"opra","name":"OPRA","route":"/trials/opra/","recorded":"enrolled 324","registry":"enrolment 358 (actual)","url":"https://clinicaltrials.gov/study/NCT02008656","severity":"low"},{"check":"enrolled-vs-registry","id":"ovhipec-1","name":"OVHIPEC-1","route":"/trials/ovhipec-1/","recorded":"enrolled 245","registry":"enrolment 242 (actual)","url":"https://clinicaltrials.gov/study/NCT00426257","severity":"low"},{"check":"enrolled-vs-registry","id":"partiqol","name":"PARTIQoL","route":"/trials/partiqol/","recorded":"enrolled 450","registry":"enrolment 454 (actual)","url":"https://clinicaltrials.gov/study/NCT01617161","severity":"low"},{"check":"enrolled-vs-registry","id":"patricia","name":"PATRICIA","route":"/trials/patricia/","recorded":"enrolled 18644","registry":"enrolment 18729 (actual)","url":"https://clinicaltrials.gov/study/NCT00122681","severity":"low"},{"check":"enrolled-vs-registry","id":"pod1um-201","name":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)","route":"/trials/pod1um-201/","recorded":"enrolled 101","registry":"enrolment 107 (actual)","url":"https://clinicaltrials.gov/study/NCT03599713","severity":"low"},{"check":"enrolled-vs-registry","id":"prodige-7","name":"PRODIGE 7","route":"/trials/prodige-7/","recorded":"enrolled 265","registry":"enrolment 264 (actual)","url":"https://clinicaltrials.gov/study/NCT00769405","severity":"low"},{"check":"enrolled-vs-registry","id":"nct03478488","name":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","route":"/trials/nct03478488/","recorded":"enrolled 480","registry":"enrolment 472 (actual)","url":"https://clinicaltrials.gov/study/NCT03478488","severity":"low"},{"check":"enrolled-vs-registry","id":"psmaddition","name":"PSMAddition","route":"/trials/psmaddition/","recorded":"enrolled 1144","registry":"enrolment 1140 (actual)","url":"https://clinicaltrials.gov/study/NCT04720157","severity":"low"},{"check":"enrolled-vs-registry","id":"rathl","name":"RATHL","route":"/trials/rathl/","recorded":"enrolled 1214","registry":"enrolment 1202 (actual)","url":"https://clinicaltrials.gov/study/NCT00678327","severity":"low"},{"check":"enrolled-vs-registry","id":"rtog-0415","name":"RTOG 0415","route":"/trials/rtog-0415/","recorded":"enrolled 1115","registry":"enrolment 1116 (actual)","url":"https://clinicaltrials.gov/study/NCT00331773","severity":"low"},{"check":"enrolled-vs-registry","id":"rtog-9408","name":"RTOG 94-08","route":"/trials/rtog-9408/","recorded":"enrolled 1979","registry":"enrolment 2028 (actual)","url":"https://clinicaltrials.gov/study/NCT00002597","severity":"low"},{"check":"enrolled-vs-registry","id":"rtog-9402","name":"RTOG 9402","route":"/trials/rtog-9402/","recorded":"enrolled 291","registry":"enrolment 299 (actual)","url":"https://clinicaltrials.gov/study/NCT00002569","severity":"low"},{"check":"enrolled-vs-registry","id":"rtog-9601","name":"RTOG 9601","route":"/trials/rtog-9601/","recorded":"enrolled 760","registry":"enrolment 840 (actual)","url":"https://clinicaltrials.gov/study/NCT00002874","severity":"low"},{"check":"enrolled-vs-registry","id":"screentrustcad","name":"ScreenTrustCAD","route":"/trials/screentrustcad/","recorded":"enrolled 55581","registry":"enrolment 55579 (actual)","url":"https://clinicaltrials.gov/study/NCT04778670","severity":"low"},{"check":"enrolled-vs-registry","id":"stevie","name":"STEVIE (vismodegib in ordinary practice)","route":"/trials/stevie/","recorded":"enrolled 1215","registry":"enrolment 1232 (actual)","url":"https://clinicaltrials.gov/study/NCT01367665","severity":"low"},{"check":"enrolled-vs-registry","id":"nct06005493","name":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct06005493/","recorded":"enrolled 280","registry":"enrolment 392 (estimated)","url":"https://clinicaltrials.gov/study/NCT06005493","severity":"low"},{"check":"enrolled-vs-registry","id":"nct01872260","name":"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer","route":"/trials/nct01872260/","recorded":"enrolled 255","registry":"enrolment 259 (actual)","url":"https://clinicaltrials.gov/study/NCT01872260","severity":"low"},{"check":"enrolled-vs-registry","id":"nct04626479","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","route":"/trials/nct04626479/","recorded":"enrolled 400","registry":"enrolment 393 (actual)","url":"https://clinicaltrials.gov/study/NCT04626479","severity":"low"},{"check":"enrolled-vs-registry","id":"summit-lung","name":"SUMMIT (lung health check study)","route":"/trials/summit-lung/","recorded":"enrolled 12773","registry":"enrolment 13035 (actual)","url":"https://clinicaltrials.gov/study/NCT03934866","severity":"low"},{"check":"enrolled-vs-registry","id":"swog-s0421-atrasentan","name":"SWOG S0421","route":"/trials/swog-s0421-atrasentan/","recorded":"enrolled 994","registry":"enrolment 1038 (actual)","url":"https://clinicaltrials.gov/study/NCT00134056","severity":"low"},{"check":"enrolled-vs-registry","id":"toga","name":"ToGA","route":"/trials/toga/","recorded":"enrolled 594","registry":"enrolment 584 (actual)","url":"https://clinicaltrials.gov/study/NCT01041404","severity":"low"},{"check":"enrolled-vs-registry","id":"tosca","name":"TOSCA","route":"/trials/tosca/","recorded":"enrolled 3759","registry":"enrolment 3756 (actual)","url":"https://clinicaltrials.gov/study/NCT00646607","severity":"low"},{"check":"enrolled-vs-registry","id":"train-2","name":"TRAIN-2","route":"/trials/train-2/","recorded":"enrolled 438","registry":"enrolment 437 (actual)","url":"https://clinicaltrials.gov/study/NCT01996267","severity":"low"},{"check":"enrolled-vs-registry","id":"transcend-cll-004","name":"TRANSCEND CLL 004","route":"/trials/transcend-cll-004/","recorded":"enrolled 137","registry":"enrolment 320 (estimated)","url":"https://clinicaltrials.gov/study/NCT03331198","severity":"low"},{"check":"enrolled-vs-registry","id":"tribe","name":"TRIBE","route":"/trials/tribe/","recorded":"enrolled 508","registry":"enrolment 509 (actual)","url":"https://clinicaltrials.gov/study/NCT00719797","severity":"low"},{"check":"us-approval-no-openfda-label","id":"i131-mibg","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","recorded":"US approval 2018","registry":"no openFDA label for \"131I-MIBG  therapy\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"aminolevulinic-acid-gleolan","name":"5-Aminolevulinic acid (oral, for glioma surgery)","route":"/drugs/aminolevulinic-acid-gleolan/","recorded":"US approval 2017","registry":"no openFDA label for \"5-Aminolevulinic acid\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"abarelix","name":"Abarelix","route":"/drugs/abarelix/","recorded":"US approval 2003","registry":"no openFDA label for \"Abarelix\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"tregzi","name":"Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq","route":"/drugs/tregzi/","recorded":"US approval 2026","registry":"no openFDA label for \"Orca-T\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"altretamine","name":"Altretamine","route":"/drugs/altretamine/","recorded":"US approval 1990","registry":"no openFDA label for \"Altretamine\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"aminoglutethimide","name":"Aminoglutethimide","route":"/drugs/aminoglutethimide/","recorded":"US approval 1980","registry":"no openFDA label for \"Aminoglutethimide\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"avapritinib","name":"Avapritinib","route":"/drugs/avapritinib/","recorded":"US approval 2020","registry":"no openFDA label for \"Avapritinib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"avelumab","name":"Avelumab","route":"/drugs/avelumab/","recorded":"US approval 2017","registry":"no openFDA label for \"Avelumab\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"capivasertib","name":"Capivasertib","route":"/drugs/capivasertib/","recorded":"US approval 2023","registry":"no openFDA label for \"Capivasertib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"copanlisib","name":"Copanlisib","route":"/drugs/copanlisib/","recorded":"US approval 2017","registry":"no openFDA label for \"Copanlisib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"cosibelimab","name":"Cosibelimab","route":"/drugs/cosibelimab/","recorded":"US approval 2024","registry":"no openFDA label for \"Cosibelimab\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"cpx-351","name":"CPX-351 (liposomal daunorubicin-cytarabine)","route":"/drugs/cpx-351/","recorded":"US approval 2017","registry":"no openFDA label for \"CPX-351\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"dolasetron","name":"Dolasetron","route":"/drugs/dolasetron/","recorded":"US approval 1997","registry":"no openFDA label for \"Dolasetron\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"estramustine","name":"Estramustine","route":"/drugs/estramustine/","recorded":"US approval 1981","registry":"no openFDA label for \"Estramustine\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"fluoxymesterone","name":"Fluoxymesterone","route":"/drugs/fluoxymesterone/","recorded":"US approval 1956","registry":"no openFDA label for \"Fluoxymesterone\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"ga68-dotatate","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/","recorded":"US approval 2016","registry":"no openFDA label for \"Gallium-68 DOTATATE\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"gedatolisib","name":"Gedatolisib","route":"/drugs/gedatolisib/","recorded":"US approval 2026","registry":"no openFDA label for \"Gedatolisib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"gilteritinib","name":"Gilteritinib","route":"/drugs/gilteritinib/","recorded":"US approval 2018","registry":"no openFDA label for \"Gilteritinib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"hpv-bivalent-vaccine","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/","recorded":"US approval 2009","registry":"no openFDA label for \"HPV bivalent vaccine\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"hpv-quadrivalent-vaccine","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/","recorded":"US approval 2006","registry":"no openFDA label for \"HPV quadrivalent vaccine\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"idelalisib","name":"Idelalisib","route":"/drugs/idelalisib/","recorded":"US approval 2014","registry":"no openFDA label for \"Idelalisib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"infigratinib","name":"Infigratinib","route":"/drugs/infigratinib/","recorded":"US approval 2021","registry":"no openFDA label for \"Infigratinib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"interferon-alfa","name":"Interferon alfa-2a/2b","route":"/drugs/interferon-alfa/","recorded":"US approval 1986","registry":"no openFDA label for \"Interferon alfa-2a\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"bcg-intravesical","name":"Intravesical BCG","route":"/drugs/bcg-intravesical/","recorded":"US approval 1990","registry":"no openFDA label for \"Intravesical BCG\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"linvoseltamab","name":"Linvoseltamab","route":"/drugs/linvoseltamab/","recorded":"US approval 2025","registry":"no openFDA label for \"Linvoseltamab\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"liposomal-irinotecan","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/","recorded":"US approval 2015","registry":"no openFDA label for \"Liposomal irinotecan\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"lunit-insight-mmg","name":"Lunit INSIGHT MMG","route":"/drugs/lunit-insight-mmg/","recorded":"US approval 2021","registry":"no openFDA label for \"Lunit INSIGHT MMG\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"hepzato","name":"Melphalan hepatic delivery system","route":"/drugs/hepzato/","recorded":"US approval 2023","registry":"no openFDA label for \"Melphalan hepatic delivery system\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"methyl-aminolevulinate","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","recorded":"US approval 2004","registry":"no openFDA label for \"Methyl aminolevulinate\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"midostaurin","name":"Midostaurin","route":"/drugs/midostaurin/","recorded":"US approval 2017","registry":"no openFDA label for \"Midostaurin\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"mirdametinib","name":"Mirdametinib","route":"/drugs/mirdametinib/","recorded":"US approval 2025","registry":"no openFDA label for \"Mirdametinib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"mitomycin","name":"Mitomycin C","route":"/drugs/mitomycin/","recorded":"US approval 1974","registry":"no openFDA label for \"Mitomycin C\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"mobocertinib","name":"Mobocertinib","route":"/drugs/mobocertinib/","recorded":"US approval 2021","registry":"no openFDA label for \"Mobocertinib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"moxetumomab-pasudotox","name":"Moxetumomab pasudotox","route":"/drugs/moxetumomab-pasudotox/","recorded":"US approval 2018","registry":"no openFDA label for \"Moxetumomab pasudotox\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"nab-paclitaxel","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/","recorded":"US approval 2005","registry":"no openFDA label for \"Nab-paclitaxel\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"necitumumab","name":"Necitumumab","route":"/drugs/necitumumab/","recorded":"US approval 2015","registry":"no openFDA label for \"Necitumumab\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"gardasil-9","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/","recorded":"US approval 2014","registry":"no openFDA label for \"Nonavalent HPV vaccine\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"odronextamab","name":"Odronextamab","route":"/drugs/odronextamab/","recorded":"US approval 2025","registry":"no openFDA label for \"Odronextamab\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"olaratumab","name":"Olaratumab","route":"/drugs/olaratumab/","recorded":"US approval 2016","registry":"no openFDA label for \"Olaratumab\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"omacetaxine","name":"Omacetaxine mepesuccinate","route":"/drugs/omacetaxine/","recorded":"US approval 2012","registry":"no openFDA label for \"Omacetaxine mepesuccinate\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"oprelvekin","name":"Oprelvekin","route":"/drugs/oprelvekin/","recorded":"US approval 1997","registry":"no openFDA label for \"Oprelvekin\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"optellum-virtual-nodule-clinic","name":"Optellum Virtual Nodule Clinic","route":"/drugs/optellum-virtual-nodule-clinic/","recorded":"US approval 2021","registry":"no openFDA label for \"Optellum Virtual Nodule Clinic\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"osimertinib","name":"Osimertinib","route":"/drugs/osimertinib/","recorded":"US approval 2015","registry":"no openFDA label for \"Osimertinib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"paige-prostate","name":"Paige Prostate Detect","route":"/drugs/paige-prostate/","recorded":"US approval 2021","registry":"no openFDA label for \"Paige Prostate Detect\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"panobinostat","name":"Panobinostat","route":"/drugs/panobinostat/","recorded":"US approval 2015","registry":"no openFDA label for \"Panobinostat\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"peginterferon-alfa-2b","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","recorded":"US approval 2011","registry":"no openFDA label for \"Peginterferon alfa-2b\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"pegylated-liposomal-doxorubicin","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/","recorded":"US approval 1995","registry":"no openFDA label for \"Pegylated liposomal doxorubicin\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"pipobroman","name":"Pipobroman","route":"/drugs/pipobroman/","recorded":"US approval 1966","registry":"no openFDA label for \"Pipobroman\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"plicamycin","name":"Plicamycin","route":"/drugs/plicamycin/","recorded":"US approval 1970","registry":"no openFDA label for \"Plicamycin\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"icad-profound-ai","name":"ProFound AI (iCAD)","route":"/drugs/icad-profound-ai/","recorded":"US approval 2018","registry":"no openFDA label for \"ProFound AI\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"megestrol-progestins","name":"Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD)","route":"/drugs/megestrol-progestins/","recorded":"US approval 1971","registry":"no openFDA label for \"Progestins\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"radioactive-iodine","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","recorded":"US approval 1951","registry":"no openFDA label for \"Radioactive iodine\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"radium-223","name":"Radium-223 dichloride","route":"/drugs/radium-223/","recorded":"US approval 2013","registry":"no openFDA label for \"Radium-223 dichloride\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"retifanlimab","name":"Retifanlimab","route":"/drugs/retifanlimab/","recorded":"US approval 2023","registry":"no openFDA label for \"Retifanlimab\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"samarium-153-lexidronam","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/","recorded":"US approval 1997","registry":"no openFDA label for \"Samarium-153 lexidronam\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"selpercatinib","name":"Selpercatinib","route":"/drugs/selpercatinib/","recorded":"US approval 2020","registry":"no openFDA label for \"Selpercatinib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"sevabertinib","name":"Sevabertinib","route":"/drugs/sevabertinib/","recorded":"US approval 2025","registry":"no openFDA label for \"Sevabertinib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"sirolimus-albumin-bound","name":"Sirolimus protein-bound particles","route":"/drugs/sirolimus-albumin-bound/","recorded":"US approval 2021","registry":"no openFDA label for \"Sirolimus protein-bound particles\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"octreotide-lanreotide","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/","recorded":"US approval 1988","registry":"no openFDA label for \"Somatostatin analogues\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"streptozocin","name":"Streptozocin","route":"/drugs/streptozocin/","recorded":"US approval 1982","registry":"no openFDA label for \"Streptozocin\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"sunvozertinib","name":"Sunvozertinib","route":"/drugs/sunvozertinib/","recorded":"US approval 2025","registry":"no openFDA label for \"Sunvozertinib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"taletrectinib","name":"Taletrectinib","route":"/drugs/taletrectinib/","recorded":"US approval 2025","registry":"no openFDA label for \"Taletrectinib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"tarlatamab","name":"Tarlatamab","route":"/drugs/tarlatamab/","recorded":"US approval 2024","registry":"no openFDA label for \"Tarlatamab\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"tilmanocept-tc99m","name":"Technetium-99m tilmanocept","route":"/drugs/tilmanocept-tc99m/","recorded":"US approval 2013","registry":"no openFDA label for \"Technetium-99m tilmanocept\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"teniposide","name":"Teniposide","route":"/drugs/teniposide/","recorded":"US approval 1992","registry":"no openFDA label for \"Teniposide\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"tivozanib","name":"Tivozanib","route":"/drugs/tivozanib/","recorded":"US approval 2021","registry":"no openFDA label for \"Tivozanib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"transpara","name":"Transpara","route":"/drugs/transpara/","recorded":"US approval 2018","registry":"no openFDA label for \"Transpara\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"trastuzumab-biosimilars","name":"Trastuzumab biosimilars","route":"/drugs/trastuzumab-biosimilars/","recorded":"US approval 2017","registry":"no openFDA label for \"Trastuzumab biosimilars\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"umbralisib","name":"Umbralisib","route":"/drugs/umbralisib/","recorded":"US approval 2021","registry":"no openFDA label for \"Umbralisib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"uracil-mustard","name":"Uracil mustard","route":"/drugs/uracil-mustard/","recorded":"US approval 1962","registry":"no openFDA label for \"Uracil mustard\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"vorasidenib","name":"Vorasidenib","route":"/drugs/vorasidenib/","recorded":"US approval 2024","registry":"no openFDA label for \"Vorasidenib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"vusolimogene-oderparepvec","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","recorded":"US approval 2026","registry":"no openFDA label for \"Vusolimogene oderparepvec\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-approval-no-openfda-label","id":"zanubrutinib","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","recorded":"US approval 2019","registry":"no openFDA label for \"Zanubrutinib\"","url":"https://open.fda.gov/apis/drug/label/","severity":"low"},{"check":"us-first-approval-missing","id":"bevacizumab-glioma","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/","recorded":"first US approval 2009 (Recurrent glioblastoma (accelerated; full approval 2017))","registry":"Drugs@FDA earliest original approval 2004","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=Bevacizumab","severity":"low"},{"check":"us-first-approval-missing","id":"dabrafenib-trametinib","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/","recorded":"first US approval 2014 (BRAF V600E/K unresectable or metastatic melanoma, combination (accelerated; each)","registry":"Drugs@FDA earliest original approval 2013","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=Dabrafenib","severity":"low"},{"check":"us-first-approval-missing","id":"decitabine-cedazuridine","name":"Decitabine + cedazuridine (oral)","route":"/drugs/decitabine-cedazuridine/","recorded":"first US approval 2020 (MDS and CMML)","registry":"Drugs@FDA earliest original approval 2013","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=Decitabine","severity":"low"},{"check":"us-first-approval-missing","id":"ifosfamide","name":"Ifosfamide","route":"/drugs/ifosfamide/","recorded":"first US approval 1988 (Germ cell testicular cancer; widely used off-label in sarcoma)","registry":"Drugs@FDA earliest original approval 1987","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=Ifosfamide","severity":"low"},{"check":"us-first-approval-missing","id":"sodium-thiosulfate","name":"Sodium thiosulfate (otoprotectant)","route":"/drugs/sodium-thiosulfate/","recorded":"first US approval 2022 (Reduce risk of ototoxicity from cisplatin in patients ≥1 month with localised, n)","registry":"Drugs@FDA earliest original approval 2012","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=Sodium%20thiosulfate","severity":"low"},{"check":"us-first-approval-missing","id":"tretinoin-atra","name":"Tretinoin (all-trans retinoic acid, ATRA)","route":"/drugs/tretinoin-atra/","recorded":"first US approval 1995 (Induction of remission in APL (t(15;17)/PML-RARA))","registry":"Drugs@FDA earliest original approval 1973","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=Tretinoin","severity":"low"},{"check":"us-first-approval-missing","id":"trifluridine-tipiracil","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/","recorded":"first US approval 2015 (Refractory metastatic colorectal cancer)","registry":"Drugs@FDA earliest original approval 1995","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=Trifluridine","severity":"low"}],"errors":[]}